Regado Biosciences 稱其融得2000萬美元的風(fēng)險(xiǎn)資金，以支持其開發(fā)一種可以控制血流的抗凝血藥，這種藥物使得手術(shù)更加安全。 Morrisville 的 Regado 公司計(jì)劃將這筆資金用于臨床試驗(yàn)以及聘用 10 至 15 名研究人員。 最新一輪的融資由Domain Associates、Quaker BioVentures 以及Aurora Funds 共同主持,。
Regado Biosciences said it raised $20 million in venture capital to develop an anticoagulant that could be turned on and off to make surgery safer.
With the money, Morrisville-based Regado plans to fund clinical trials in humans and hire 10 to 15 researchers.
"This financing provides further validation of the Regado technology and will allow us to build on our progress," said chief executive Douglas Gooding, a former venture capitalist who spun Regado out of Duke University Medical Center's surgery department in 2001.
Gooding said the capital infusion should be enough to fund operations through third quarter 2007, when the 4-year-old company might look to complete clinical trials or sell the operation.
The latest funding round was led by Domain Associates of Princeton, N.J., along with Quaker BioVentures of Philadelphia and Aurora Funds of Durham. Individual investors also participated.
Regado's lead drug, REG1, would be the first anticoagulant with an antidote that can prompt and halt blood thinning during coronary and vascular surgeries.
Gooding said the money will bring REG1 to an advanced clinical stage where it may become attractive to companies looking to market an anticoagulant that helps surgeons control bleeding.
"The Regado drug-antidote technology is truly novel," said Jesse Treu of Domain Associates. Treu and P. Sherill Neff of Quaker BioVentures are on Regado's board.
Other sizable investment pools for Triangle businesses this year include $20 million for IRM, a Durham medical-devices and equipment maker; $30 million for Motricity, a Durham cell-phone applications company; and $18 million for ChannelAdvisor, a Morrisville company that helps people buy and sell online.
